APA (7th ed.) Citation

JP, B., T, K., L, L., W, W., T, R. G., JM, S., . . . AM, Z. (2026). Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood cancer journal. https://doi.org/10.1038/s41408-026-01543-6

Chicago Style (17th ed.) Citation

JP, Bewersdorf, et al. "Outcomes of Patients with Higher-risk Myelodysplastic Syndromes/neoplasms Treated with Hypomethylating Agents + Venetoclax-an Analysis from the International Consortium for MDS (icMDS) VALIDATE Database." Blood Cancer Journal 2026. https://doi.org/10.1038/s41408-026-01543-6.

MLA (9th ed.) Citation

JP, Bewersdorf, et al. "Outcomes of Patients with Higher-risk Myelodysplastic Syndromes/neoplasms Treated with Hypomethylating Agents + Venetoclax-an Analysis from the International Consortium for MDS (icMDS) VALIDATE Database." Blood Cancer Journal, 2026, https://doi.org/10.1038/s41408-026-01543-6.